Co-Diagnostics Forms New Business Unit to Develop AI-Powered Diagnostics

Co-Diagnostics, Inc. (Salt Lake City, UT, USA) has formed a new artificial intelligence (AI) business unit to integrate the company's existing and planned AI applications into its Co-Dx Primer Ai platform.

The company's next-generation diagnostics technology, enhanced by proprietary AI models, enables real-time PCR diagnostics at the point-of-care. Co-Dx anticipates that allocating resources to the newly formed AI business unit will enable the company to develop proprietary AI-powered diagnostics more efficiently and reduce time-to-market for new tests. The company also believes that future AI tools will be able to leverage the analytics yielded from widespread deployment and commercialization of the Co-Dx PCR Pro to improve situational awareness during a health crisis, and potentially predict outbreaks and pandemics before they occur.

Co-Dx's AI models support internal data and workflow orchestration, as well as Co-Primers design and optimization. Future models will enhance automated test interpretation and create predictive epidemiological awareness. These models will operate in tandem with the company's HIPAA-compliant Co-Dx cloud platform and internal databases to form the foundation of Co-Dx Primer Ai.

"Since our founding in 2013, Co-Diagnostics has been at the forefront of PCR technology innovation, beginning with the introduction of the revolutionary Co-Primers technology, and later with the development of the Co-Dx PCR platform to help close the diagnostics access gap," said Dwight Egan, Co-Dx Chief Executive Officer. "Now, as the rate of adoption of enterprise artificial intelligence increases and AI applications continue to grow in ubiquity and utility, we have begun incorporating these next-generation tools to help increase operational efficiency, minimize human error, improve outcomes in real-time point-of-care testing, and truly give physicians, patients, and communities the Power to Know."

Related Links:
Co-Diagnostics, Inc.